COVID-19 Pneumonia Hospitalization Tied to New-Onset Dementia

MONDAY, May 2, 2022 (HealthDay News) -- Approximately 3 percent of patients with pneumonia associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection subsequently develop dementia, according to a study published in the April issue of Open Forum Infectious Diseases.
Adnan I. Qureshi, M.D., from University of Missouri in Columbia, and colleagues examined the risk for a new diagnosis of dementia following more than 30 days after the index hospitalization for COVID-19. The analysis included 10,403 patients with pneumonia associated with SARS-CoV-2 infection.
The researchers found that 3 percent of participants developed new-onset dementia during a median period of 182 days. The risk for new-onset dementia was significantly higher with pneumonia associated with SARS-CoV-2 infection versus pneumonia unrelated to SARS-CoV-2 infection (odds ratio, 1.3) when adjusting for age, gender, race/ethnicity, hypertension, diabetes mellitus, hyperlipidemia, nicotine dependence/tobacco use, alcohol use/abuse, atrial fibrillation, previous stroke, and congestive heart failure. The association persisted even after additional adjustment for the occurrence of stroke, septic shock, and intubation/mechanical ventilation during index hospitalization (odds ratio, 1.3).
"The findings suggest a role for screening for cognitive deficits among COVID-19 survivors," Qureshi said in a statement. "If there is evidence of impairment during screening and if the patient continues to report cognitive symptoms, a referral for comprehensive assessment may be necessary."
One author disclosed financial ties to the pharmaceutical industry.
Related Posts
Cancer Screenings Rise in States With Mandatory Paid Sick Leave
THURSDAY, March 2, 2023 (HealthDay News) -- Many Americans are not getting...
La vacuna contra COVID en aerosol nasal arroja resultados prometedores en la fase inicial de un estudio
JUEVES, 12 de octubre de 2023 (HealthDay News) -- Una nueva investigación señala...
Medicare Spending Would Increase $2.0 to $5.1 Billion With Lecanemab
THURSDAY, May 18, 2023 (HealthDay News) -- If eligible patients received...
